Scholarlink

<p>The organized cervical cancer screening program (oKFE-Zervix) was introduced in Germany on January&#xa0;1, 2020 as a&#xa0;standardized screening procedure, replacing the opportunistic, cytology-based screening that had been in place since 1971. The program is based on the oKFE directive of the Federal Joint Committee and is directed at asymptomatic women aged 20&#xa0;years and older who are insured under the statutory health insurance system. The primary aim of the program is to achieve a&#xa0;significant reduction in cervical cancer incidence and mortality through the early detection of persistent high-risk human papillomaviruses (HPV) infections and the resulting precancerous lesions and invasive disease. To this end, age-adapted, structured diagnostic and follow-up algorithms are applied. Continuous quality assurance and outcome evaluations of the oKFE-Zervix by independent institutions aim to ensure long-term optimization of screening quality and to contribute to the sustainable improvement of cervical cancer prevention. The first evaluation of the oKFE-Zervix shows overall moderate participation rates, a&#xa0;high proportion of normal findings, and HPV positivity rates in line with expectations. However, the limited observation period does not yet allow for a&#xa0;robust assessment of the program’s effectiveness in reducing cervical cancer incidence or mortality, and the program is therefore currently continued in its existing form.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Schnittstelle Praxis und Klinik – der Abklärungsalgorithmus in der Richtlinie des organisierten Krebsfrüherkennungsprogramms für das Zerixkarzinom

  • 期刊论文

  • 发表日期：

    2026年5月12日

查看全文
  • Sarah Schott,
  • Gerd Böhmer

摘要

The organized cervical cancer screening program (oKFE-Zervix) was introduced in Germany on January 1, 2020 as a standardized screening procedure, replacing the opportunistic, cytology-based screening that had been in place since 1971. The program is based on the oKFE directive of the Federal Joint Committee and is directed at asymptomatic women aged 20 years and older who are insured under the statutory health insurance system. The primary aim of the program is to achieve a significant reduction in cervical cancer incidence and mortality through the early detection of persistent high-risk human papillomaviruses (HPV) infections and the resulting precancerous lesions and invasive disease. To this end, age-adapted, structured diagnostic and follow-up algorithms are applied. Continuous quality assurance and outcome evaluations of the oKFE-Zervix by independent institutions aim to ensure long-term optimization of screening quality and to contribute to the sustainable improvement of cervical cancer prevention. The first evaluation of the oKFE-Zervix shows overall moderate participation rates, a high proportion of normal findings, and HPV positivity rates in line with expectations. However, the limited observation period does not yet allow for a robust assessment of the program’s effectiveness in reducing cervical cancer incidence or mortality, and the program is therefore currently continued in its existing form.